AbbVie shares consolidate as technicals point to continued selling pressure: weekly report

Traders Union
All News
Financial News
AbbVie rises 1.90% this week

Highlights

ABBV remains under medium-term selling pressure, trading below key moving averages but above long-term support at $176.45.
Momentum indicators, including MACD and RSI, signal continued weakness with sellers dominating and oversold conditions persisting.
Price is expected to fluctuate between $200.60 and $208.75, with a low probability of upside and increased risk if $200 support fails.

Earnings beat and guidance hike lift sentiment as immunology sales surge

AbbVie reported strong Q1 2026 results, including net revenues of approximately $15.0 billion, up 12.4% year-over-year, and adjusted EPS of $2.65, surpassing consensus estimates. The company raised its full-year adjusted EPS guidance and highlighted significant sales growth in its immunology portfolio, driven by Skyrizi and Rinvoq. AbbVie also invested over $5 billion in business development and announced a research collaboration with BigHat Biosciences to advance antibody therapeutics.

Seller control dominates as momentum weakens over the week

On the weekly timeframe, ABBV remains under pressure, trading below its MA-20 and MA-50 but comfortably above the MA-200 for long-term support. Weekly MACD is in Sell territory, ADX is Neutral, and the Awesome Oscillator reflects continuing downside bias. RSI indicates a Sell, while both CCI and Stochastic RSI show oversold conditions, and Bull/Bear Power remains deeply negative, all pointing to ongoing seller dominance. The technical picture reveals weak momentum, with limited evidence of sustained buying from weekly oscillators.

Sideways to lower outlook as resistance caps bullish scenarios

For the next 5 trading days, ABBV is anticipated to fluctuate within a corridor of $200.60 to $208.75. Weekly indicators signal a strong likelihood of sideways or downward movement, with less than a 20% chance of an upward breakout. A bullish shift would require ABBV to close decisively above the MA-50 resistance. If support near $200.60 fails, further declines toward the MA-200 level could emerge.

Parshwa Turakhiya, analyst, notes that AbbVie showed a modest recovery this week, but the stock remains locked under medium-term moving averages and continues to reflect weak momentum. He acknowledges that strong earnings and revised EPS guidance lifted sentiment, yet weekly indicators still paint a technically fragile picture dominated by sellers. The analyst sees ABBV trading sideways or drifting lower unless it can regain the MA-50 resistance at $213.33, with the $200.60 support now critical. Turakhiya believes sentiment is cautious while the market digests recent gains. "This week, I’ll be watching for any sustained move above $213.33 to trigger renewed buyer interest — but until then, patience and capital protection are my priorities."

In a recent review, analysts emphasized persistent seller pressure on AbbVie despite improved fundamentals, with technical indicators largely signaling caution and unresolved momentum. The current outlook reinforces this assessment, as ABBV’s weak technical setup suggests that any near-term recovery may be limited until a decisive close above the MA-50 shifts momentum in the stock’s favor.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.